{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:41:16Z","timestamp":1761043276144,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.urolonc.2022.02.003","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T15:28:31Z","timestamp":1645889311000},"page":"409.e1-409.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6945-8261","authenticated-orcid":false,"given":"Herney Andr\u00e9s","family":"Garc\u00eda-Perdomo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie L\u00f3pez","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.02.003_bib0001","unstructured":"National Cancer Institute. SEER cancer stat facts: bladder cancer. Reports on Cancer. 2019. p. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"issue":"8","key":"10.1016\/j.urolonc.2022.02.003_bib0002","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2022.02.003_bib0003","first-page":"62","article-title":"Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer","volume":"8","author":"Pang","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0004","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0005","series-title":"JBI Manual for Evidence Synthesi","article-title":"Scoping reviews","author":"Peters","year":"2020"},{"year":"2018","series-title":"Assessment of efficacy and safety of durvalumab plus BCG compared to the standard therapy with BCG in non-muscle invasive bladder cancer (POTOMAC)","key":"10.1016\/j.urolonc.2022.02.003_bib0006"},{"year":"2019","series-title":"Atezolizumab plus one-year BCG bladder instillation in BCG-naive high-risk non-muscle invasive bladder cancer patients (ALBAN)","key":"10.1016\/j.urolonc.2022.02.003_bib0007"},{"year":"2017","series-title":"Pembrolizumab and BCG solution in treating patients with recurrent non-muscle-invasive bladder cancer","key":"10.1016\/j.urolonc.2022.02.003_bib0008"},{"year":"2018","series-title":"A study of nivolumab or nivolumab plus experimental medication BMS-986205 with or without Bacillus Calumette-Guerin (BCG) in BCG unresponsive bladder cancer that has not invaded into the muscle wall of the bladder (CheckMate 9UT)","key":"10.1016\/j.urolonc.2022.02.003_bib0009"},{"year":"2016","series-title":"Safety and pharmacology study of atezolizumab alone and in combination with Bacille Calmette-Gu\u00e9rin (BCG) in high-risk non-muscle-invasive bladder cancer (NMIBC) participants","key":"10.1016\/j.urolonc.2022.02.003_bib0010"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0011","first-page":"1","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"year":"2019","series-title":"Study of sasanlimab (PF-06801591) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer (CREST)","key":"10.1016\/j.urolonc.2022.02.003_bib0012"},{"year":"2020","series-title":"Atezolizumab and BCG in high risk BCG na\u00efve non-muscle invasive bladder cancer (NMIBC) patients (BladderGATE) (BladderGATE)","author":"Oncosur","key":"10.1016\/j.urolonc.2022.02.003_bib0013"},{"year":"2018","series-title":"Pembrolizumab (MK-3475) as first-line therapy for high risk T1 non-muscle-invasive bladder cancer","key":"10.1016\/j.urolonc.2022.02.003_bib0014"},{"year":"2015","series-title":"Study of pembrolizumab (MK-3475) in participants with high risk non-muscle invasive bladder cancer (MK-3475-057\/KEYNOTE-057)","key":"10.1016\/j.urolonc.2022.02.003_bib0015"},{"year":"2018","series-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in high-risk non-muscle invasive bladder cancer (HR NMIBC) (MK-3475-676\/KEYNOTE-676)","key":"10.1016\/j.urolonc.2022.02.003_bib0016"},{"year":"2017","series-title":"Atezolizumab in treating patients with recurrent BCG-unresponsive non-muscle invasive bladder cancer","key":"10.1016\/j.urolonc.2022.02.003_bib0017"},{"year":"2019","series-title":"Avelumab plus Bacille Calmette-Guerin (BCG) in patients with non-muscle invasive bladder cancer","key":"10.1016\/j.urolonc.2022.02.003_bib0018"},{"year":"2019","series-title":"\u00bfA study comparing the efficacy and safety of nivolumab in combination with Bacillus Calmette-Guerin (BCG) versus BCG alone in participants with high-risk non-muscle invasive bladder cancer (HR NMIBC) (CheckMate 7G8)","key":"10.1016\/j.urolonc.2022.02.003_bib0019"},{"issue":"2","key":"10.1016\/j.urolonc.2022.02.003_bib0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0021","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s00120-020-01233-6","article-title":"Immunonkologische Therapieoptionen des nicht-muskelinvasiven Urothelkarzinoms","volume":"59","author":"Kramer","year":"2020","journal-title":"Urologe"},{"issue":"7457","key":"10.1016\/j.urolonc.2022.02.003_bib0022","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.urolonc.2022.02.003_bib0023","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s00120-020-01233-6","article-title":"Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer","volume":"59","author":"Kramer","year":"2020","journal-title":"Urol A"},{"issue":"8","key":"10.1016\/j.urolonc.2022.02.003_bib0024","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0025","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patientswith locally advanced and metastatic urothelial carcinoma whohave progressed following treatment with platinum-based che-motherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0026","unstructured":"Health World Organization. Global cancer observatory. Global cancer statistics to inform cancer control and research. 2019."},{"key":"10.1016\/j.urolonc.2022.02.003_bib0027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ucl.2019.09.012","article-title":"Immunooncology approaches to salvage treatment for non-muscle invasive bladder cancer","volume":"47","author":"Sathianathen","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0028","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.02.003_bib0029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.urolonc.2022.02.003_bib0030","first-page":"e7","article-title":"PD03-02 Phase 3 results of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:26:17Z","timestamp":1761042377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1078143922000382"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}